Core Viewpoint - The Zacks Style Scores provide a framework for investors to evaluate stocks based on value, growth, and momentum, enhancing the decision-making process for stock selection [2][3][7]. Summary by Category Zacks Style Scores - The Zacks Style Scores rate stocks using a grading system from A to F, with A being the highest score indicating a better chance of outperforming the market [3]. - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6]. Value Score - The Value Score helps investors identify undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3]. Growth Score - The Growth Score emphasizes a company's financial health and future growth potential, considering projected and historical earnings, sales, and cash flow [4]. Momentum Score - The Momentum Score assists investors in capitalizing on stock price trends, utilizing metrics like one-week price changes and monthly earnings estimate changes [5]. VGM Score - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6]. Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8]. Stock Example: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics, with about 75% of revenue coming from the U.S. market [12]. - Stryker holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of B, with a Momentum Style Score of B, indicating potential for investors [13][14].

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, helping investors identify securities likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to find those with sustainable growth potential [4] Momentum Score - The Momentum Style Score identifies trends in stock prices and earnings outlooks, helping investors time their positions effectively [5] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with attractive value, strong growth forecasts, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks (4 or 5) should be avoided, even if they have high Style Scores, due to declining earnings forecasts [10] Company Spotlight: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics [11] - The company has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a Growth Style Score of B indicating an expected year-over-year earnings growth of 11.2% for the current fiscal year [12] - Recent upward revisions in earnings estimates and a positive earnings surprise average of +2.9% make Stryker a notable option for growth investors [12][13]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating better performance potential [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [4] Momentum Score - Assesses stocks based on price trends and earnings outlook, helping investors capitalize on upward or downward movements [5] VGM Score - Combines all three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth, and momentum [6] Zacks Rank Integration - The Zacks Rank uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988 [7] - There can be over 800 stocks rated 1 or 2, making it essential to utilize Style Scores for better selection [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: Stryker (SYK) - Stryker is a leader in medical technology, generating approximately 60% of sales from MedSurg & Neurotechnology and 40% from Orthopaedics [11] - The company has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a strong Momentum Style Score of A [12] - Recent upward revisions in earnings estimates indicate positive growth potential, with the Zacks Consensus Estimate for fiscal 2025 at $13.55 per share [12][13]

Core Insights - Solventum (SOLV) reported $2.16 billion in revenue for Q2 2025, a year-over-year increase of 3.8% and an EPS of $1.69 compared to $1.56 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company’s stock has returned -2.2% over the past month, underperforming the Zacks S&P 500 composite's +1.2% change, and currently holds a Zacks Rank 4 (Sell) [3] Financial Performance Metrics - Net Sales in MedSurg reached $1.22 billion, surpassing the $1.18 billion average estimate, reflecting a +4.8% year-over-year change [4] - Net Sales in Purification and Filtration were $252 million, exceeding the estimated $242.52 million, with a +5.9% year-over-year change [4] - Net Sales in Health Information Systems totaled $339 million, slightly above the $334.42 million estimate, marking a +3.4% year-over-year change [4] - Net Sales in Dental Solutions amounted to $338 million, compared to the estimated $332.9 million, representing a +2.1% year-over-year change [4] - Operating Income in MedSurg was $210 million, below the estimated $215.41 million [4] - Operating Income in Purification and Filtration was $48 million, significantly above the estimated $20.15 million [4] - Operating Income in Health Information Systems reached $120 million, exceeding the estimated $112.01 million [4] - Operating Income in Dental Solutions was $96 million, above the estimated $89.41 million [4]

Core Insights - Solventum (SOLV) is expected to report quarterly earnings of $1.45 per share, a decline of 7.1% year-over-year, with revenues projected at $2.12 billion, reflecting a 1.9% increase compared to the previous year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating analysts have reassessed their initial estimates [1][2] - The stock has returned -4% over the past month, underperforming the Zacks S&P 500 composite, which increased by 1% [5] Revenue Estimates - Analysts forecast 'Net Sales- MedSurg' to reach $1.18 billion, indicating a year-over-year change of +1.6% [3] - 'Net Sales- Purification and Filtration' is predicted to be $242.52 million, reflecting a year-over-year increase of +1.9% [4] - The consensus estimate for 'Net Sales- Health Information Systems' stands at $334.42 million, suggesting a +2% change from the year-ago quarter [4] - 'Net Sales- Dental Solutions' is expected to arrive at $332.90 million, indicating a +0.6% year-over-year change [4]

Core Insights - Solventum (SOLV) reported revenue of $2.07 billion for the quarter ended March 2025, reflecting a year-over-year increase of 2.7% [1] - The company's EPS was $1.34, down from $2.08 in the same quarter last year, but exceeded the consensus estimate of $1.19, resulting in an EPS surprise of +12.61% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $2 billion, yielding a revenue surprise of +3.37% [1] Financial Performance Metrics - Net Sales in MedSurg reached $1.16 billion, exceeding the average estimate of $1.10 billion from three analysts [4] - Net Sales in Purification and Filtration were $242 million, slightly below the average estimate of $242.25 million [4] - Net Sales in Health Information Systems totaled $329 million, surpassing the average estimate of $319.96 million [4] - Net Sales in Dental Solutions amounted to $328 million, exceeding the average estimate of $325.61 million [4] - Operating Income in MedSurg was $206 million, below the average estimate of $229.10 million [4] - Operating Income in Purification and Filtration was $35 million, above the average estimate of $31.92 million [4] - Operating Income in Health Information Systems reached $109 million, exceeding the average estimate of $104.45 million [4] - Operating Income in Dental Solutions was $78 million, below the average estimate of $95.98 million [4] Stock Performance - Solventum's shares have returned -4.5% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]